Imagine a testosterone therapy that yields the same benefits, but eliminates the usual concerns—no more worrying about sudden spikes in testosterone leading to enlarged prostates, mood swings, and more. Picture a treatment without the risk of hair loss because of raised DHT levels or gynecomastia because of elevated estradiol levels. With this new FDA-approved oral testosterone therapy, there’s no need for complex protocols. It offers a simple, convenient solution—easy to take for patients, and straightforward for you to manage.

At Day 90 in a six-month clinical study of 139 men with low testosterone, patients who completed the study (n=127), 96% of patients achieved normal testosterone levels. But that's not all. Patients also experienced a 2x increase in mean Free Testosterone Levels and a 30% decrease in mean SHBG levels.

KYZATREX is a controlled substance (CIII) because it contains testosterone. In the phase 3 clinical trial for KYZATREX (n=155), 4 patients (2.6%) reported high blood pressure. A total of 5 patients (3.2%) began taking new antihypertensive medications after study start. No patient increased their dose of antihypertensive medication. It is not known if KYZATREX is safe or effective in males younger than 18 years old. Improper use may affect bone growth in children. KYZATREX is not meant for use by women.